Work

Efficacy and safety of oral tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphomas: A systematic review and proportionality meta-analysis.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e19045

Authors: Haris Mumtaz Malik, Beenish Sabir, Shahroz Ansar, Shazia Hashim, Adnan Bhat, Javed Iqbal, Allahdad Khan, Muhammad Ibrahim, Maria Qadri, Noor ul ain Saleem, Shamikha Cheema, Muhammad Riyyan

Institutions: Rawalpindi Medical University, Baqai Medical University, University of Florida, Hamad Medical Corporation, Bannu Medical College, Jinnah Sindh Medical University, FMH College of Medicine & Dentistry, King Edward Medical University

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410822627

Cites:

Cited by:

Related to: 10